A federal judge ruled that Elan must amend its marketing deal with Johnson & Johnson for multiple sclerosis drug Tysabri because it violates Elan's partnership with Biogen Idec on the product. The dispute stems from J&J's purchase of a stake in Elan that gives J&J an option to finance Elan's purchase of Tysabri rights owned by Biogen.

Related Summaries